Similarly, in an ongoing phase I clinical trial [CAR2BRAIN (NCT03383978, clinicaltrials.gov (accessed on 1 February 2021))], which has undergone rigorous evaluation by regulatory authorities as well by an ethical committee, NK-92 cells are administered intracranially as a therapeutic approach in patients with recurrent or refractory ErbB2-positive glioblastoma. Here, ERBB2 is linked to glioblastoma.